| __timestamp | Neurocrine Biosciences, Inc. | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 46425000 | 2242216 |
| Thursday, January 1, 2015 | 81491000 | 4536244 |
| Friday, January 1, 2016 | 94291000 | 5184803 |
| Sunday, January 1, 2017 | 121827000 | 3068742 |
| Monday, January 1, 2018 | 160524000 | 7178000 |
| Tuesday, January 1, 2019 | 200000000 | 16267000 |
| Wednesday, January 1, 2020 | 275000000 | 23191000 |
| Friday, January 1, 2021 | 328100000 | 21453000 |
| Saturday, January 1, 2022 | 463800000 | 15265000 |
| Sunday, January 1, 2023 | 565000000 | 25189000 |
| Monday, January 1, 2024 | 731100000 |
In pursuit of knowledge
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. has consistently outpaced Soleno Therapeutics, Inc. in R&D investment. From 2014 to 2023, Neurocrine's R&D expenses surged by over 1,100%, reaching a peak in 2023. In contrast, Soleno's R&D spending grew by approximately 1,000% during the same period, but from a much smaller base.
Neurocrine's strategic focus on innovation is evident, with its R&D expenses in 2023 being more than 20 times that of Soleno. This significant investment underscores Neurocrine's commitment to advancing its pipeline and maintaining a competitive edge. As the biotech landscape evolves, these spending patterns highlight the varying strategies companies employ to drive growth and innovation.
Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Neurocrine Biosciences, Inc.
R&D Insights: How Novartis AG and Soleno Therapeutics, Inc. Allocate Funds
Vertex Pharmaceuticals Incorporated or Neurocrine Biosciences, Inc.: Who Invests More in Innovation?
Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Verona Pharma plc
Neurocrine Biosciences, Inc. or CymaBay Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Novavax, Inc.
Exelixis, Inc. or Soleno Therapeutics, Inc.: Who Invests More in Innovation?
R&D Insights: How Lantheus Holdings, Inc. and Soleno Therapeutics, Inc. Allocate Funds
Research and Development Expenses Breakdown: Corcept Therapeutics Incorporated vs Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.